A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

被引:49
作者
Hermida, L
Rodríguez, R
Lazo, L
Silva, R
Zulueta, A
Chinea, G
López, C
Guzmán, MG
Guillén, G
机构
[1] Ctr Ingn Genet & Biotecnol, Div Vacunas, Havana 10600, Cuba
[2] Inst Med Trop Pedro Kouri, Havana, Cuba
关键词
dengue-2; escherichia coli; P64k; envelope protein;
D O I
10.1016/j.jviromet.2003.09.024
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A gene fragment encoding for the amino acids (aa) 286-426 from the dengue Envelope (E) protein was expressed in Escherichia coli as two forms of fusion proteins. In one case, the E fragment was fused to the first 45 aa of the P64k protein from Neisseria meningitidis (PD2) while, in the other, it was inserted within the lipoil-binding domain of the aforementioned bacterial protein (PD3). PD2 was obtained as insoluble form within the cytoplasm of the bacteria while PD3 was distributed equally as soluble and insoluble forms. The insoluble forms of each protein as well as the soluble fraction of PD3 were semipurified to test the antigenicity and the immunogenicity in mice. The forms containing the entire P64k protein exhibited the highest recognition with different polyclonal and monoclonal antibodies. Consequently, the neutralizing antibodies elicited by the recombinant proteins were higher in the case of PD3 forms than with PD2, independently of the solubility status. In addition, mice inoculated with the semipurified insoluble form of PD3 were partially protected against lethal challenge with dengue-2 virus, administered by intracerebral inoculation. The results suggested the folding and carrier capacity of the P64k protein over the E fragment, converting PD3 as an attractive vaccine candidate against dengue-2 virus. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 34 条
[1]   Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes [J].
Anderson, R ;
Wang, SL ;
Osiowy, C ;
Issekutz, AC .
JOURNAL OF VIROLOGY, 1997, 71 (06) :4226-4232
[2]   PROTEIN MEASUREMENT USING BICINCHONINIC ACID - ELIMINATION OF INTERFERING SUBSTANCES [J].
BROWN, RE ;
JARVIS, KL ;
HYLAND, KJ .
ANALYTICAL BIOCHEMISTRY, 1989, 180 (01) :136-139
[3]  
BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376
[4]   ANTIGENIC RELATIONSHIPS BETWEEN FLAVIVIRUSES AS DETERMINED BY CROSS-NEUTRALIZATION TESTS WITH POLYCLONAL ANTISERA [J].
CALISHER, CH ;
KARABATSOS, N ;
DALRYMPLE, JM ;
SHOPE, RE ;
PORTERFIELD, JS ;
WESTAWAY, EG ;
BRANDT, WE .
JOURNAL OF GENERAL VIROLOGY, 1989, 70 :37-43
[5]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[6]   TECHNIQUES FOR HEMAGGLUTINATION AND HEMAGGLUTINATION-INHIBITION WITH ARTHROPOD-BORNE VIRUSES [J].
CLARKE, DH ;
CASALS, J .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1958, 7 (05) :561-573
[7]   NUCLEOTIDE-SEQUENCE AND DEDUCED AMINO-ACID-SEQUENCE OF THE STRUCTURAL PROTEINS OF DENGUE TYPE-2 VIRUS, JAMAICA GENOTYPE [J].
DEUBEL, V ;
KINNEY, RM ;
TRENT, DW .
VIROLOGY, 1986, 155 (02) :365-377
[8]   IMMUNIZATION OF MICE WITH RECOMBINANT VACCINIA VIRUS EXPRESSING AUTHENTIC DENGUE VIRUS NONSTRUCTURAL PROTEIN NS1 PROTECTS AGAINST LETHAL DENGUE VIRUS ENCEPHALITIS [J].
FALGOUT, B ;
BRAY, M ;
SCHLESINGER, JJ ;
LAI, CJ .
JOURNAL OF VIROLOGY, 1990, 64 (09) :4356-4363
[9]   FLAVIVIRUS TYPE-SPECIFIC ANTIGENS PRODUCED FROM FUSIONS OF A PORTION OF THE E-PROTEIN GENE WITH THE ESCHERICHIA-COLI TRPE GENE [J].
FONSECA, BAL ;
KHOSHNOOD, K ;
SHOPE, RE ;
MASON, PW .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 44 (05) :500-508
[10]   A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial [J].
Gonzalez, G ;
Crombet, T ;
Catala, M ;
Mirabal, V ;
Hernandez, JC ;
Gonzalez, Y ;
Marinello, P ;
Guillen, G ;
Lage, A .
ANNALS OF ONCOLOGY, 1998, 9 (04) :431-435